MedTrace Logo

Visualization of Carotid Atherosclerosis by 68Ga-MSA

NCT01893489 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-08-27

No results posted yet for this study

Summary

Until now, no specific atherosclerosis-targeting agent labeled with positron emitter is not yet available. Investigators developed neomannosyl human serum albumin(MSA) for the terminal mannose residues of MSA binding with the mannose receptors of macrophages in atherosclerosis, and investigators investigate whether 68Ga-MSA can be a novel agent for non-invasive molecular imaging of carotid atherosclerotic lesion in PET.

Conditions

  • Atherosclerosis
  • Carotid Atherosclerosis
  • Noninvasive Imaging of Atherosclerosis

Interventions

OTHER

68Gallium-MSA

68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging

Sponsors & Collaborators

  • SHIN JIN MEDICS

    collaborator UNKNOWN

  • Korea University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01893489 on ClinicalTrials.gov